Evaluate the Efficacy and Safety of Genexol®-PM Compared to Genexol® in Recurrent or Metastatic Breast Cancer
Phase III trial to evaluate the efficacy and safety of Genexol®-PM compared to Genexol® in subjects with recurrent or metastatic breast cancer.
Breast Cancer
DRUG: Genexol-PM®|DRUG: Genexol®
Objective Response Rate, Evaluate the efficacy of Genexol®-PM versus Genexol® in subjects with recurrent or metastatic breast cancer based on Objective Response Rate., 6 months
Overall Survival, Progress Free Survival, Time to Tumor Progression, Duration of Overall Response, To evaluate the efficacy of Genexol®-PM relative to Genexol® as measured by Overall Survival, Progress Free Survival, Time to Tumor Progression, Duration of Overall Response., Event driven|Safety and toxicity, To compare the safety and toxicity of Genexol®-PM with those of Genexol®, Throughout study
Phase III trial to evaluate the efficacy and safety of Genexol®-PM compared to Genexol® in subjects with recurrent or metastatic breast cancer.